title: Preserved function of late-outgrowth endothelial cells in medically treated hypertensive patients under well-controlled conditions.
abstract: Endothelial progenitor cells (EPCs) participate in renal repair, but their number and function may be impaired by exposure to cardiovascular risk factors. The number of circulating EPCs is decreased in essential and renovascular hypertensive patients, but the effects of hypertension on EPC function are incompletely understood. We hypothesized that EPC function was preserved under well-controlled conditions in treated hypertensive patients. Patients with atherosclerotic renal artery stenosis (ARAS; n=22) or essential hypertension (n=24) were studied during controlled sodium intake and antihypertensive regimen. Late-outgrowth EPCs were isolated from the inferior vena cava (IVC) and renal vein blood of ARAS and essential hypertension patients and a peripheral vein of matched normotensive controls (n=18). The angiogenic function of EPCs was assessed in vitro, and multidetector computed tomography was used to measure single-kidney hemodynamics and function in ARAS and essential hypertension patients. Inflammatory biomarkers and EPC homing signal levels and renal release were calculated. Inferior vena cava and renal vein-obtained EPC function were similar in ARAS and essential hypertension patients and comparable to that in normal controls (tube length, 171.86±16.846, 191.09±14.222, 174.925±19.774 μm, respectively). Function of renal vein-obtained EPCs directly correlated with stenotic kidney glomerular filtration rate, EPC homing factors, and anti-inflammatory mediator levels in ARAS patients. Therefore, EPC function was relatively preserved in ARAS patients, although it directly correlated with renal function. Adequate EPC function supports the feasibility of using autologous EPCs as a therapeutic option in essential and renovascular hypertensive patients. Homing signals and inflammatory mediators may potentially regulate EPC angiogenic function.
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Zhi
authors.initials: Z
authors.lastname: Chen
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Sandra M S
authors.initials: SM
authors.lastname: Herrmann
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Xiangyang
authors.initials: X
authors.lastname: Zhu
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Kyra L
authors.initials: KL
authors.lastname: Jordan
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Monika L
authors.initials: ML
authors.lastname: Gloviczki
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Amir
authors.initials: A
authors.lastname: Lerman
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.).
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Textor
authors.affiliation: From the Divisions of Nephrology and Hypertension (Z.C., S.M.S.H., X.Z., K.L.J., M.L.G., S.C.T., L.O.L.) and Cardiovascular Diseases (A.L., L.O.L.), Mayo Clinic, Rochester, MN; and Division of Nephrology, First Hospital of Jilin University, Jilin, China (Z.C.). lerman.lilach@mayo.edu.
authors.forename: Lilach O
authors.initials: LO
authors.lastname: Lerman
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000097:blood / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D001808:Blood Vessels / Q000473:pathology / Q000503:physiopathology; D002465:Cell Movement; D049109:Cell Proliferation; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006978:Hypertension, Renovascular / Q000097:blood / Q000503:physiopathology; D018836:Inflammation Mediators / Q000097:blood; D007668:Kidney / Q000098:blood supply / Q000503:physiopathology; D011446:Prospective Studies; D012078:Renal Artery Obstruction / Q000097:blood / Q000503:physiopathology; D012079:Renal Circulation; D012082:Renal Veins / Q000378:metabolism / Q000473:pathology; D013234:Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D014682:Vena Cava, Inferior / Q000378:metabolism / Q000473:pathology
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D018836:Inflammation Mediators
keywords: hypertension, essential; hypertension, renovascular